Linked Life Data

16027014

Source:http://linkedlifedata.com/resource/pubmed/id/16027014

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-9-13
pubmed:abstractText
Dendritic-cell-derived exosomes (DEX) secreted after dendritic cell loading with tumor peptides were found to mediate tumor rejection in mice. This observation prompted us to demonstrate that MHC class I/peptide complexes harbored onto exosomal membranes were capable of priming cytotoxic T cells and to mediate rejection of tumors expressing the relevant antigens. Moreover, DEX also promote NK cell activation in immunocompetent mice and NK cell-dependent antitumor effects. The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1079-9796
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-5
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
The potential of exosomes in immunotherapy of cancer.
pubmed:affiliation
ERIT-M 02-08 INSERM, Unité d'Immunologie, Département de Biologie Clinique, (+12), Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't